BridgeBio Pharma, Inc.
BBIO
Hisse Senetlerindeki Sıralama
#1615
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Hisse Fiyatı
$68.06
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$13.31B
Değişim (1 gün)
2.52%
Değişim (1 yıl)
20.97%
Ülke
US
Ticaret BridgeBio Pharma, Inc. (BBIO)
Kategori
Healthcare
BridgeBio Pharma, Inc. (BBIO) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 195.79M
BridgeBio Pharma, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 195.79M'dir. December 2023 sonunda şirketin 162.79M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
BridgeBio Pharma, Inc. (BBIO) için 2017 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 195.79M | 5.22% |
| 2024 | 186.08M | 14.30% |
| 2023 | 162.79M | 10.39% |
| 2022 | 147.47M | 2.16% |
| 2021 | 144.36M | 22.34% |
| 2020 | 118.00M | 12.27% |
| 2019 | 105.10M | 13.83% |
| 2018 | 92.33M | 0.00% |
| 2017 | 92.33M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 29.68% |
US
|
|
| 396.00M | 102.26% |
US
|
|
| 478.91M | 144.61% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -68.24% |
NL
|
